Safinamide
Safinamide has been studied in 1 paper since 2022: none in people yet, 1 in cells. No study of it in people or animals has been published yet. The newest paper, Jan 1, 2022: “Safinamide protects against amyloid β (Aβ)-induced oxidative stress and cellular senescence in M17 neuronal cells”.
- 1 lab in 1 country
- Funder: Nanchang University
- Cells1
What did studies of Safinamide find?
2Studies of Safinamide measured 2 outcomes; the most studied are cellular senescence (1 study) and oxidative stress and ROS signaling (1).
Cellular senescence
downin human cells1
1 study
Cellular senescence
downin human cells1
Safinamide decreases cellular senescence in human cells.
“Safinamide treatment significantly ameliorated senescence-associated-β-galactosidase (SA-β-gal)-positive cells”
CellsAβ1−42 oligomers-stimulated M17 cells100 or 200 nM
Bioengineered
Oxidative stress and ROS signaling
downin human cells1
1 study
Oxidative stress and ROS signaling
downin human cells1
Safinamide decreases oxidative stress and ROS signaling in human cells.
“safinamide ameliorated Aβ1−42 oligomers-induced oxidative stress in M17 cells”
CellsAβ1−42 oligomers-stimulated M17 cells100 or 200 nM
Bioengineered